June 15, 2022

Post-COVID-19 Vaccination Breast Screenings Revealed Enlarged Lymph Nodes

The development of ipsilateral axillary lymphadenopathy is not uncommon in women who receive COVID-19 vaccines. A recent study found that about 14% of women who underwent breast screenings had enlarged lymph nodes after getting their shots. Find out what else a recent study has determined about the condition and its potential severity.


RAAS Inhibitors Effective at Reducing Risk of Brain Aneurysm Rupture

A new study looking at the effectiveness of renin-angiotensin-aldosterone system (RAAS) inhibitors—a class of blood pressure–lowering medicine—in preventing brain aneurysm rupture appears to be practice-changing, according to the American Heart Association (AHA). The AHA reports that RAAS inhibitors had an 18% lower risk of a ruptured aneurysm compared with those who were prescribed other blood pressure medications. Read more.

Two Immune-Modulating Drugs Reduce Mortality in COVID-19 Patients

The immune systems of some COVID-19 patients go into overdrive, causing excessive inflammation that can lead to acute respiratory distress syndrome, multiple organ failure, and even death. In trials, infliximab and abatacept appear to improve patients' clinical status and reduce mortality rates, although they did not significantly shorten the time to recovery. Learn more about these medications and their effects in COVID-19 patients.


Tirzepatide Shows Promise for Use as a Weight Loss Medication

Tirzepatide, a once-weekly SC injectable peptide approved by the FDA for type 2 diabetes, has agonist activity at both the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. That is why a new trial tested it as a weight loss drug for patients without diabetes. The researchers from Yale University School of Medicine in New Haven, Connecticut, say the results are very promising. Read more.

Facebook   Twitter   USP Google App   USP itunes App
U.S. Pharmacist
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Advertisement Advertisement